Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

This trial is testing whether adding adebrelimab (an immunotherapy drug) to a standard chemotherapy regimen (XELOX: oxaliplatin + capecitabine) combined with bevacizumab (a drug that blocks tumor blood vessel growth) improves outcomes as a first-line treatment for people with metastatic colorectal cancer that has a specific molecular profile (MSS/pMMR) and cannot be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed metastatic colorectal cancer that cannot be surgically removed - Your tumor has been tested and is MSS (microsatellite stable) or pMMR - You have at least one measurable tumor site - You are in good physical condition (ECOG 0-1) with at least 12 weeks expected survival - Your blood counts, liver, kidney, and thyroid function are adequate **You may NOT be eligible if...** - You have already received chemotherapy for metastatic colorectal cancer - You have autoimmune conditions requiring treatment - You are pregnant or breastfeeding - You have significant heart or lung disease Talk to your doctor to see if this trial is right for you.